As capital has become more selective, investors have understandably gravitated toward later-stage, de-risked assets. Pharmaceutical companies have responded by allocating more capital toward licensing and acquisitions of those assets because of their higher probability of success, shorter development timelines, and more predictable returns. That is a rational investment strategy for an individual company. Whether it … Continue reading Is Today’s Biotech Investment Borrowing Growth from the Future?